Week in Review: Curon Bio Acquires Lymphoma Drug Rights in $150 Million Deal

Deals and Financings Shanghai Curon Biopharma acquired China rights to a treatment for a novel lymphoma from Rhizen Pharma of Switzerland in a $149.5 million deal; EdiGene of Beijing raised $67 million in a Series B round to develop its genome editing technologies for genetic diseases and cancer drugs; ImmuneOnco, a Shanghai immunotherapy company, completed a $25 million Series B financing for novel cancer drugs; HitGen will acquire Vernalis Limited, a Cambridge , UK CRO, from Ligand Pharma for $25 million; CBC Group merged two of its Shanghai ophthalmologic and CNS companies, AffaMed and EverInsight, into a single entity; The story of how ReadCoor, a Decheng-backed Boston company with an In Situ sequencing technology, was acquired by10x Genomics for $350 million; COVID-19 Pandemic Singapore 's Aslan Pharma announced plans to develop ASLAN003, its next-gen DHODH inhibitor, in autoimmune conditions and COVID-19; Company News   Qihan Biotech of Hangzhou will apply genome editing to cell therapies and organ transplants to develop human stem cells with reduced immunogenicity; PPD, a global CRO, announced plans to build a large new facility in Suzhou to support China drug development; Cue Health, a San Diego company backed by Decheng, received a $481 million US grant to ramp up production of its rapid point-of-care coronavirus tests; Trials and Approvals Suzhou Innovent Bio and Eli Lilly announced their Rituxan biosimilar was approved in China for lymphoma and leukemia indications; An Ascletis Pharma subsidiary, Gannex Pharma, was approved to begin US clinical trials of its novel candidate for non-alcoholic steatohepatitis. Stock Symbols: (SHA: 688222) (NSDQ: LGND) (NSDQ: ASLN) (NSDQ: PPD) (HK: 01801) (NYSE: LLY) (HKEX: 1672) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.